Anatabloc Gains Approval for First Human Clinical Study

August 2012
Journal of Gerontological Nursing;Aug2012, Vol. 38 Issue 8, p5
Academic Journal
The article reports that Rocks Creek Pharmaceuticals Inc. has received an approval to begin a human clinical study on the safety and efficacy of the nutritional supplement Antabloc in individuals with Alzheimer's disease (AD).


Related Articles

  • Alzheimer’s treatment to enter second trial. Henderson, Tom // Crain's Detroit Business;6/6/2011, Vol. 27 Issue 23, p0006 

    The article focuses on the planned second clinical trial of a zinc-based treatment for Alzheimer's disease symptoms by Adeona Pharmaceuticals Inc. It says that the company will enroll over 100 patients aged 70 and above. It tells that if the trial succeed in proving the drugs' efficacy, the...

  • Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Zetterberg, Henrik; Mattsson, Niklas; Blennow, Kaj; Olsson, Olsson // Alzheimer's Research & Therapy;2010, Vol. 2 Issue 6, p1 

    In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment...

  • Improving Drug Trials for Mild to Moderate Alzheimer's Disease. Hogan, David B. // Canadian Journal of Neurological Sciences;Mar2007 Supplement 1, Vol. 34, pS97 

    The article focuses on concerns raised in literature about the design and methodology of drug trials for mild to moderate Alzheimer's disease. The article also make recommendations to deal with the limitations of the clinical trials. Concerns include undue focus on statistical rather than...

  • NTRR To Begin Clinical Trials of Pure Plus This Week.  // Biomedical Market Newsletter;2/7/2012, Vol. 21, p1 

    The article focuses on the expected beginning of clinical trials on natural weight loss supplement named Pure Plus, by Neutra Corp. Neutra is recruiting qualified volunteers for testing the supplements. The company is developing products to compete with the fast growing nutraceuticals industry....

  • OUTCOMES FOR DISEASE MODIFYING TRIALS. Wilcock, G. // Journal of Nutrition, Health & Aging;Jul/Aug2007, Vol. 11 Issue 4, p318 

    The article discusses the importance of clinical outcomes for Alzheimer's disease (AD) modifying drug trials. It notes that a randomized, parallel, two arm placebo-controlled design is the preferred approach because of its trial duration that shows balance between the time required to manifest a...

  • Brain storm. Gliddon, Joshua // Bulletin with Newsweek;8/8/2006, Vol. 124 Issue 6532, p30 

    The article informs that the compound PBT2 is being tested to cure Alzheimer's disease. An experiment on mouse shows the possibility, but higher doses proved toxic. This phase-I trial shows safety of the compound, but it does not show if it works. Results of the mouse test show reduction in...

  • Alzheimer's Disease Clinical Trials: Where are we now? Cummings, Jeffrey // Canadian Journal of Neurological Sciences;Feb2006, Vol. 33 Issue 1, p5 

    The article reflects on the status of clinical trials for possible treatment of Alzheimer's disease (AD). It presents current symptomatic therapies including cholinesterase inhibitors and memantine delay deterioration. The endeavor in conducting randomized clinical trials for tacrine leads to an...

  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations. SCHNEIDER, L. S. // Journal of Nutrition, Health & Aging;Apr2010, Vol. 14 Issue 4, p295 

    Recommendations for clinical trials methods for ‘pre-dementia,’ ‘prodromal,’ or early Alzheimer’s disease are discussed. Early AD can be considered as subsets of both ‘amnestic MCI’ and ‘probable AD.’ In principle, it can be...

  • Forest's Namenda provides functional and behavioral benefits in patients with moderate/severe AD.  // PharmaWatch: CNS;June 2004, Vol. 3 Issue 6, p8 

    Announces the results of phase III clinical trial of Forest Laboratories Inc. evaluating the treatment of patients with moderate to severe Alzheimer's disease with a combination of two contemporary Alzheimer's drugs. Response of patients treated with a combination of Namenda and donepezil;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics